Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-Bromo-7-nitroindazole is a synthetic small molecule belonging to the indazole class of organic compounds. It acts as a potent and selective inhibitor of neuronal nitric oxide synthase (nNOS), with greater potency than its analog, 7-nitroindazole. It also inhibits other isoforms of nitric oxide synthase (NOS), including endothelial NOS (eNOS) and inducible NOS (iNOS), but with lower potency. The compound has been used primarily in research settings to study the role of nNOS in neurobiology, neuroprotection, and memory formation. There are no approved clinical indications for this compound; it is considered experimental and is not approved for human therapeutic use[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-bromo-7-nitroindazole.